Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 May 6;17(1):75.
doi: 10.1007/s11657-022-01110-z.

A retrospective observational study of osteoporosis management after a fragility fracture in primary care

Alan Bell  1 , David L Kendler  2 , Aliya A Khan  3 , Marla Shapiro C M  1 , Anne Morisset  4 , Jean-Pierre Leung  5 , Maureen Reiner  6 , Stephen M Colgan  6 , Lubomira Slatkovska  7 , Millicent Packalen  8
Affiliations
Observational Study

A retrospective observational study of osteoporosis management after a fragility fracture in primary care

Alan Bell et al. Arch Osteoporos. .

Abstract

In many countries, osteoporosis is predominantly managed by primary care physicians; however, management after a fragility fracture has not been widely investigated. We describe osteoporosis care gaps in a real-world patient cohort. Our findings help inform initiatives to identify and overcome obstacles to effective management of patients after fragility fracture.

Purpose: A fragility fracture is a major risk factor for subsequent fracture in adults aged ≥ 50 years. This retrospective observational study aimed to characterize post-fracture management in Canadian primary care.

Methods: A total of 778 patients with an index fragility fracture (low-trauma, excluding small bones) occurring between 2014 and 2016 were identified from medical records at 76 primary care centers in Canada, with follow-up until January 2018.

Results: Of 778 patients (80.5% female, median age [IQR] 73 [64-80]), 215 were on osteoporosis treatment and 269 had osteoporosis diagnosis recorded prior to their index fracture. The median follow-up was 363 (IQR 91-808) days. Of patients not on osteoporosis treatment at their index fracture, 60.2% (n = 339/563) remained untreated after their index fracture and 62.2% (n = 23/37) continued untreated after their subsequent fracture. After their index fracture, fracture risk assessment (FRAX or CAROC) was not performed in 83.2% (n = 647/778) of patients, and 59.9% (n = 466/778) of patients did not receive bone mineral density testing. Of patients without osteoporosis diagnosis recorded prior to their index date, 61.3% (n = 300/489) remained undiagnosed after their index fracture. At least one subsequent fracture occurred in 11.5% (n = 86/778) of patients.

Conclusion: In the primary care setting, fragility fracture infrequently resulted in osteoporosis treatment or fracture risk assessment, even after multiple fragility fractures. These results suggest a fragility fracture is not recognized as a major risk factor for subsequent fracture and its occurrence does not prompt primary care physicians to intervene. These data urge initiatives to identify and overcome obstacles to primary care physicians' effective management of patients after fragility fractures.

Keywords: Fracture; Osteoporosis; Primary care; Real-world data; Secondary prevention.

PubMed Disclaimer

Conflict of interest statement

AB has received research grants, speaker honoraria, and/or consultancies from Amgen, AstraZeneca, Bausch Health, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, HLS Therapeutics, Janssen, Novartis, Pfizer, Sanofi, and Spectrum Therapeutics. DLK has received research grants, speaker honoraria, and/or consultancies from Alexion, Amgen, BioSyent, and Radius Health. AAK has received research grants from Alexion, Amgen, Ascendis, Chugai, Radius Health, Takeda, and Ultragenyx. MS has received research grants, speaker honoraria, and/or consultancies from Amgen, Aspen, Astellas, Bayer, BioSyent, Duchesnay, GlaxoSmithKline, Merck, Mithra, Pfizer, Searchlight, Sprout, Sunovion, and Therapeutics MD. AM has received speaker honoraria and/or consultancies from Amgen, Eli Lilly, and Sanofi. MR, SMC, LS, and MP are/were employees at the time of study completion and own stock in Amgen. JPL declares no conflict of interest.

Figures

Fig. 1
Fig. 1
Study schema
Fig. 2
Fig. 2
Flow diagram of sites and patients included in the index fracture cohort
Fig. 3
Fig. 3
Osteoporosis treatment initiation
Fig. 4
Fig. 4
Fracture risk and BMD assessments
Fig. 5
Fig. 5
Osteoporosis diagnosis (n = 758)
See this image and copyright information in PMC

References

    1. Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A et al (2020) American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis: 2020 update. Endocr Pract 26(1 Suppl):1–46. 10.4158/gl-2020-0524suppl - PubMed
    1. Khan AA, Choudur HN, Lentle B (2020) Diagnosis of osteoporosis: clinical and densitometric analysis. Can Assoc Radiol J 72(2):326. 10.1177/0846537120944385 - PubMed
    1. International Osteoporosis Foundation. About osteoporosis. Available from: https://www.osteoporosis.foundation/health-professionals/about-osteoporosis. Accessed 2 Feb 2021
    1. Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD (2006) Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum 35(5):293-305. 10.1016/j.semarthrit.2005.11.001 - PubMed
    1. Public Health Agency of Canada. Osteoporosis and related fractures in Canada: report from the Canadian Chronic Disease Surveillance System, 2020. https://www.canada.ca/en/public-health/services/publications/diseases-co.... Accessed 15 Jan 2021 - PubMed

Publication types

Substances